📊 STTK Key Takeaways
Is Shattuck Labs, Inc. (STTK) a Good Investment?
Shattuck Labs is a development-stage pharmaceutical company with zero commercial revenue and deteriorating operating performance, burning $13.4M quarterly with only ~6-7 quarters of cash runway at current rates. While the balance sheet remains strong with $90.4M cash and zero debt, the absence of revenue generation and lack of insider buying activity signal significant execution risk and uncertainty around pathway to profitability.
Shattuck Labs, Inc. Key Strengths (STTK)
- Strong cash position of $90.4M provides runway for operations
- Zero debt and exceptional liquidity ratios (22.06x current ratio)
- Declining losses with EPS improvement of 53% YoY shows operational discipline
STTK Stock Risks: Shattuck Labs, Inc. Investment Risks
- Virtually zero revenue with 82.5% YoY decline indicates failed commercialization efforts
- Operating cash burn of $13.4M per quarter with limited runway (est. 6-7 quarters)
- Development-stage pharma with high execution risk and uncertain regulatory pathway
- Zero insider Form 4 filings in 90 days suggests no insider confidence
Key Metrics to Watch
- Revenue traction and clinical trial/regulatory approval milestones
- Quarterly cash burn rate and updated cash runway estimates
- Operating loss trajectory and path to cash flow breakeven
Shattuck Labs, Inc. (STTK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 22.06x current ratio provides a solid financial cushion.
STTK Profit Margin, ROE & Profitability Analysis
STTK vs Healthcare Sector: How Shattuck Labs, Inc. Compares
How Shattuck Labs, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Shattuck Labs, Inc. Stock Overvalued? STTK Valuation Analysis 2026
Based on fundamental analysis, Shattuck Labs, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Shattuck Labs, Inc. Balance Sheet: STTK Debt, Cash & Liquidity
STTK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Shattuck Labs, Inc.'s revenue has declined by 81% over the 5-year period, indicating business contraction. The most recent EPS of $-1.49 indicates the company is currently unprofitable.
STTK Revenue Growth, EPS Growth & YoY Performance
STTK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$13.7M | $-0.13 |
| Q3 2025 | $1.0M | -$10.1M | $-0.14 |
| Q2 2025 | N/A | -$12.5M | $-0.24 |
| Q1 2025 | N/A | -$13.7M | $-0.27 |
| Q3 2024 | $686.0K | -$16.7M | $-0.33 |
| Q2 2024 | $200.0K | -$18.5M | $-0.42 |
| Q1 2024 | $57.0K | -$18.5M | $-0.37 |
| Q3 2023 | $212.0K | -$20.7M | $-0.58 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Shattuck Labs, Inc. Dividends, Buybacks & Capital Allocation
STTK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Shattuck Labs, Inc. (CIK: 0001680367)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STTK
What is the AI rating for STTK?
Shattuck Labs, Inc. (STTK) has an AI grade of C with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STTK's key strengths?
Claude: Strong cash position of $90.4M provides runway for operations. Zero debt and exceptional liquidity ratios (22.06x current ratio).
What are the risks of investing in STTK?
Claude: Virtually zero revenue with 82.5% YoY decline indicates failed commercialization efforts. Operating cash burn of $13.4M per quarter with limited runway (est. 6-7 quarters).
What is STTK's revenue and growth?
Shattuck Labs, Inc. reported revenue of $0.0.
Does STTK pay dividends?
Shattuck Labs, Inc. does not currently pay dividends.
Where can I find STTK SEC filings?
Official SEC filings for Shattuck Labs, Inc. (CIK: 0001680367) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STTK's EPS?
Shattuck Labs, Inc. has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is STTK's fundamental grade?
Based on our AI fundamental analysis in June 2026, Shattuck Labs, Inc. has a C grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is STTK stock overvalued or undervalued?
Valuation metrics for STTK: ROE of -15.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is STTK's AI grade for 2026?
Our dual AI analysis gives Shattuck Labs, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STTK's free cash flow?
Shattuck Labs, Inc.'s operating cash flow is $-13.4M, with capital expenditures of $71.0K.
How does STTK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -15.4% (avg: 15%), current ratio 22.06 (avg: 2).